4174 Stock Overview A biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
OBI Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for OBI Pharma Historical stock prices Current Share Price NT$57.60 52 Week High NT$92.90 52 Week Low NT$57.60 Beta 0.99 1 Month Change -8.57% 3 Month Change -22.27% 1 Year Change -20.44% 3 Year Change -49.47% 5 Year Change -57.49% Change since IPO -52.79%
Recent News & Updates
Third quarter 2024 earnings released: NT$2.27 loss per share (vs NT$2.48 loss in 3Q 2023) Nov 19
OBI Pharma, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 25
Second quarter 2024 earnings released: NT$2.36 loss per share (vs NT$1.79 profit in 2Q 2023) Aug 17
OBI Pharma, Inc. to Report Q2, 2024 Results on Aug 02, 2024 Jul 24
OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA May 31
New major risk - Financial position May 19 See more updates
Third quarter 2024 earnings released: NT$2.27 loss per share (vs NT$2.48 loss in 3Q 2023) Nov 19
OBI Pharma, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Oct 25
Second quarter 2024 earnings released: NT$2.36 loss per share (vs NT$1.79 profit in 2Q 2023) Aug 17
OBI Pharma, Inc. to Report Q2, 2024 Results on Aug 02, 2024 Jul 24
OBI Pharma, Inc. Files the Application of Phase I/II human clinical trial for OBI-992 TROP2 ADC to TFDA May 31
New major risk - Financial position May 19
OBI Pharma, Inc. to Report Q1, 2024 Results on May 10, 2024 Apr 28
Full year 2023 earnings released: NT$4.57 loss per share (vs NT$7.27 loss in FY 2022) Mar 29 Obi Pharma, Inc. Announces the Termination of Obi-3424-001 Trial While Continuing the Collaboration Of obi-3424 with Partners
OBI Pharma, Inc. Announces Adagloxad Simolenin (OBI-822) Receives Positive 1st Interim Analysis Recommendation, Recommending the Continues of the Phase III TNBC Trial Feb 01
OBI Pharma, Inc. Announces Resignation of Yun Yen as Chairperson and Director, Effective December 29, 2023 Dec 21
Obi Pharma, Inc. Files the Application of Phase I/II Human Clinical Trial for OBI-992 TROP2 ADC to US FDA Dec 02
OBI Pharma, Inc. Announces CFO Changes Nov 08 OBI Pharma, Inc. Announces CFO Changes
Less than half of directors are independent Aug 11
Second quarter 2023 earnings released: EPS: NT$1.79 (vs NT$1.50 loss in 2Q 2022) Aug 08
OBI Pharma, Inc. Announces Appointment of Yun Yen as the Chairman Jun 29
OBI Pharma, Inc. Announces Appointment of Yun Yen as Natural-Person Director Jun 28
OBI Pharma, Inc. Announces COVID-19 Vaccine, BCVax, Has Been Granted by TFDA to Proceed to Phase I Clinical Trial Jun 03
OBI Pharma Appoints Heidi Wang as Chief Executive Officer Jun 02
Full year 2022 earnings released: NT$7.27 loss per share (vs NT$7.69 loss in FY 2021) Mar 17
Obi Pharma, Inc. Files Application for Phase II Human Clinical Trial of First-In-Class Novel Prodrug, Obi-3424, to TFDA Feb 03
OBI Pharma, Inc. Announces Demise of Chairman of the Board, Michael Chang Dec 30
Less than half of directors are independent Nov 16
Second quarter 2022 earnings released: NT$1.50 loss per share (vs NT$2.09 loss in 2Q 2021) Aug 15 OBI Pharma, Inc. announced that it expects to receive TWD 800 million in funding Aug 09
Obi Pharma Announces Discontinuation of the Phase 1/2 Study of Iis Antibody- OBI 888 Jul 06 OBI Pharma, Inc. Announces Audit Committee Changes
First quarter 2022 earnings released: NT$1.52 loss per share (vs NT$1.16 loss in 1Q 2021) May 16
Less than half of directors are independent Apr 27
OBI Pharma, Inc. Announces That AEMPS of Spain Revokes Previous Approval for the Active Cancer Immunotherapy, OBI-822, to Proceed to Phase III Clinical Trial Apr 08
Full year 2021 earnings released: NT$7.69 loss per share (vs NT$7.34 loss in FY 2020) Mar 28
OBI Pharma, Inc. Announces TFDA Grants Approval for Active Cancer Immunotherapy OBI-833 to Proceed to Phase II Clinical Trial Feb 24 OBI Pharma, Inc. Announces Preliminary Findings of Their In-House Developed Next-Generation COVID-19 Vaccine, BCVax
OBI Pharma, Inc. Announces Phase 2 Studies Patient Enrollment for Obi-999 and Obi-3424 Jan 25
Directorate General of Drug Supplies and Drugs of Peru Grants OBI Pharma, Inc.'s OBI-822 (Adagloxad Simolenin) to Proceed to Phase III Clinical Trial Dec 19
OBI Files the Application for Phase II clinical Trial for Obi-833, an Active Cancer immunotherapy, to TFDA Dec 16
Third quarter 2021 earnings released: NT$1.64 loss per share (vs NT$2.02 loss in 3Q 2020) Nov 15
Second quarter 2021 earnings released: NT$2.09 loss per share (vs NT$1.67 loss in 2Q 2020) Aug 12
First quarter 2021 earnings released: NT$1.16 loss per share (vs NT$1.67 loss in 1Q 2020) May 13
OBI Pharma, Inc. Announces First Patient Enrolled on SWOG Cancer Research Network's OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL Apr 27
Full year 2020 earnings released: NT$7.34 loss per share (vs NT$7.76 loss in FY 2019) Mar 30
OBI Pharma, Inc., Annual General Meeting, Jun 21, 2021 Mar 17
OBI Pharma (GTSM:4174) Shareholders Booked A 69% Gain In The Last Year Mar 12
New 90-day high: NT$153 Mar 03
Here's Why OBI Pharma (GTSM:4174) Can Manage Its Debt Despite Losing Money Jan 18
New 90-day high: NT$124 Dec 14
If You Had Bought OBI Pharma's (GTSM:4174) Shares Five Years Ago You Would Be Down 82% Nov 26
OBI Pharma, Inc. Announces Presentation of Data from the OBI-833 Phase 1 Clinical Study at European Society of Clinical Oncology Asia 2020 Virtual Scientific Program Nov 20
Third quarter 2020 earnings released: NT$2.02 loss per share Nov 10
New 90-day low: NT$108 Sep 24
Price target lowered to NT$148 Sep 01
First half earnings released Aug 12 Shareholder Returns 4174 TW Biotechs TW Market 7D -1.7% -2.6% -2.1% 1Y -20.4% -0.8% 25.6%
See full shareholder returns
Return vs Industry: 4174 underperformed the TW Biotechs industry which returned -0.8% over the past year.
Return vs Market: 4174 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility Is 4174's price volatile compared to industry and market? 4174 volatility 4174 Average Weekly Movement 4.7% Biotechs Industry Average Movement 4.5% Market Average Movement 4.4% 10% most volatile stocks in TW Market 7.8% 10% least volatile stocks in TW Market 2.1%
Stable Share Price: 4174 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 4174's weekly volatility (5%) has been stable over the past year.
About the Company OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
Show more OBI Pharma, Inc. Fundamentals Summary How do OBI Pharma's earnings and revenue compare to its market cap? 4174 fundamental statistics Market cap NT$13.20b Earnings (TTM ) -NT$2.11b Revenue (TTM ) NT$69.55m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 4174 income statement (TTM ) Revenue NT$69.55m Cost of Revenue NT$138.93m Gross Profit -NT$69.38m Other Expenses NT$2.04b Earnings -NT$2.11b
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -9.19 Gross Margin -99.75% Net Profit Margin -3,028.89% Debt/Equity Ratio 1.7%
How did 4174 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/22 07:46 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources OBI Pharma, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Pinghan Hsieh Capital Securities Corporation Li-chun Chang Jih Sun Securities Investment Consulting Co., Ltd. Yijun Chen SinoPac Securities Investment Service
Show 0 more analysts 
